• BIBASWAN MISHRA Department of Pharmaceutics, Institute of Pharmacy and Technology, Salipur, Cuttack 754202, Odisha, India
  • BISWARANJAN MOHANTY Department of Pharmaceutics, Institute of Pharmacy and Technology, Salipur, Cuttack 754202, Odisha, India




Etoricoxib, Bilayer technology, Once daily tablet, Release kinetics


Objective: In the present work, the main objective was to develop bilayer extended release matrix tablets of etoricoxib by providing a loading dose followed by maintenance dose that expected to improve the therapeutic efficacy of the medication with less toxic effect.

Methods: Bilayer tablets of etoricoxib was developed successfully with the meticulous proportion of release controlling Hydroxy propyl methyl cellulose K100 (HPMC K100) and lactose. The tablets were prepared by wet granulation technique. Granules for immediate layer and extended layer for different formulations were prepared separately. The formulations were developed and evaluations were performed to examine the parameters that affect the in vitro performance of the tablets. The drug-excipient compatibility was ensured by Fourier transform infrared spectroscopy (FTIR) study.

Results: The values of physical parameters of all formulations were found within appreciable limit. Formulation containing HPMC K 100 and lactose in the proportion of 2:1 in the extended release layer was able to release 26.22% of drug in 15 min and shown a steady release of drug for an extended period of 12 h. The dissolution data was put in Korsemeyer–Peppas model in order to find out n value, which describes the drug release mechanism. The n-value of different formulations were found to be variable. The Fourier transform infrared spectroscopy (FTIR) study revealed absence of any other new peaks and also no differences in the positions of the absorption bands in the bilayer tablet F8 that indicate the lack of significant interactions between etoricoxib and other excipients.

Conclusion: It had been concluded that once daily immediate-and extended release bilayer tablet of etoricoxib can be formulated with profound physical characteristics and dissolution properties. This resulted in reducing the daily dose and thus minimise the cardiovascular toxicity of etoricoxib.


Download data is not yet available.


Agrawal NGB, Porras AG. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers. J Clin Pharmacol 2001;41:1106–10.

Rodrigues AD, Halpin RA, Geer LA. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers. Drug Metab Dispos 2003;31:224–32.

Cochrane DJ, Jarvis B, Keating GM. Etoricoxib. Drugs 2002;62:2637–51.

Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, et al. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558–66.

Goutte F, Guemguem F, Dragan C, Vergnault G, Wehrle P. Power of experimental design studies for the validation of pharmaceutical processes: case study of a multilayer tablet manufacturing process. Drug Dev Ind Pharm 2002;28:841–8.

Abebe A, Akseli I, Sprockel O, Kottala N, Cuitino AM. Review of bilayer tablet technology. Int J Pharm 2014;461:549–58.

Efentakis M, Naseef H, Vlachou M. Two-and three-layer tablet drug delivery systems for oral sustained release of soluble and poorly soluble drugs. Drug Dev Ind Pharm 2010;36:903–16.

Aburahma MH, Yel SH. Novel sustained-release fast-disintegrating multiunit compressed tablets of lornoxicam containing Eudragit RS coated chitosan-alginate beads. Pharm Dev Technol 2011;16:316–30.

Qiang F, Xiaonan S, Yanxian H, Mo L, Jingru L, Jin S, et al. Once-daily amoxicillin immediate-and extended-release bilayer tablets. Powder Tech 2016;301:405-11.

Acharya S, Patra S, Pani NR. Optimization of HPMC and carbopol concentrations in non-effervescent floating tablet through factorial design. Carbohydr Polym 2014;102:360–8.

He W, Y Li, R Zhang, Z Wu, L Yin. Gastro floating bilayer tablet for the sustained release of metformin and immediate released of pioglitazone: preparations and in vitro/in vivo evaluations. Int J Pharma 2014;476:223–31.

Das MK, Sahu BP, Hazarika JNR. Development of bilayer tablets for immediate and controlled release of allicin. Int J Curr Pharm Res 2017;9:153-60.

Mishra B, Sahoo J, Dixit PK. Enhanced bioavailability of cinnarizine nanosuspensions by particle size engineering: optimisation and physicochemical investigations. Mat Sci Eng C 2016;63:62-9.

Gerry S. Preformulation predictions from small amounts of compound as an aid to candidate drug selection. In: Mark G. (Ed). Pharmaceutical preformulation and formulation: a practical guide from candidate drug selection to commercial dosage form: CRC Press Florida USA; 2004. p. 21-2.

Kamble S, Poul B, Udapurkar P. Bilayer tablet of tramadol and gabapentin for combination pharmacotherapy of neuropathic pain: development and characterization. Int J Appl Pharm 2018;10:100-7.

Roy SK, Naskar S, Kundu S, Koutsu K. Formulation and evaluation of sustained release bilayer tablets of propranolol hydrochloride. Int J Pharm Pharm Sci 2015;7:264-9.

Panda N, Reddy AV, Reddy GVS, Sultana A. Formulation design and in vitro evaluation of bilayer sustained release matrix tablets of doxofylline. Int J Pharm Pharm Sci 2015;7:74-83.

Parashar T, Singh N. Formulation and in vitro evaluation of bilayer tablet of atenolol for biphasic drug release. Asian J Pharm Clin Res 2018;11:114-9.

Mishra B, Sahoo J, Dixit PK. Formulation and process optimization of naproxen nanosuspensions stabilized by hydroxy propyl methyl cellulose. Carbohydr Polym 2015;127:300-8.



How to Cite

MISHRA, B., & MOHANTY, B. (2019). ONCE DAILY IMMEDIATE-AND EXTENDED-RELEASE BILAYER TABLETS OF ETORICOXIB: A STUDY ON THE RELEASE KINETICS. International Journal of Applied Pharmaceutics, 11(5), 230–235. https://doi.org/10.22159/ijap.2019v11i5.31638



Original Article(s)